Document Detail

Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension.
MedLine Citation:
PMID:  9926277     Owner:  NLM     Status:  MEDLINE    
Increased sympathetic activity seems to play an important role in the pathogenesis and development of complications of atherosclerotic origin in patients with essential hypertension (EH). The aim of this study was to evaluate the effect of a new antihypertensive agent, moxonidine (M), on microalbuminuria (urine albumin excretion, UAE), plasma thrombomodulin (TM), and tissue plasminogen activator inhibitor (PAI-1) in patients with mild to moderate EH associated with increased UAE. Fifty-eight patients (32 M, 26 F) with EH and microalbuminuria, with a mean age of 56.6 +/- 8.2 years and a body mass index (BMI) of 23.8 +/- 3.1 kg/m2 who responded to M therapy (0.3-0.4 mg/daily) were studied before and after their blood pressure control. The 24-hour urine albumin excretion (RIA method), as well as TM and PAI-1 plasma levels (ELISA method), were determined before and 6 months after the initiation of treatment under moxonidine therapy. At the end of the 6-month period, all patients remained normotensive. The 24-hour urine albumin excretion had decreased to 24.5 +/- 6.4 vs. 32.3 +/- 7.2 ug/min before therapy (P < 0.001). The plasma TM levels had decreased to 44.0 +/- 7 vs. 51.0 +/- 9 ng/mL before therapy (P < 0.01), and PAI-1 levels had also decreased to 11.5 +/- 4.5 vs. 15.8 +/- 8 IU/mL before therapy (P < 0.05). The results of our study suggest that in hypertensive patients with microalbuminuria, moxonidine, an imidazoline I1-receptor agonist, a new centrally acting antihypertensive agent, significantly reduces urine albumin excretion as well as thrombomodulin and PAI-1 levels. These preliminary findings demonstrate a favorable effect on renal function and endothelial homeostatic mechanisms (maintenance of haemostatic balance).
P G Krespi; T K Makris; A N Hatzizacharias; P Triposkiadis; C Tsoukala; D Kyriaki; V Votteas; M Kyriakidis
Related Documents :
8094087 - An enzyme immunoassay for the determination of taxol and taxanes in taxus sp. tissues a...
2498417 - Use of retinol-binding protein and prealbumin as indicators of the response to nutritio...
3371297 - Need for re-evaluation of serum albumin in an african population.
6694777 - Membranous nephropathy: predictors of terminal renal failure.
2886587 - A new method for measuring the free fraction of cyclosporin in plasma by equilibrium di...
19487947 - Thioredoxin in human and experimental sepsis.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  12     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-03-30     Completed Date:  1999-03-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  463-7     Citation Subset:  IM    
Athens University, Medical School, Department of Cardiology, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / drug therapy*
Antihypertensive Agents / therapeutic use*
Imidazoles / therapeutic use*
Middle Aged
Plasminogen Activator Inhibitor 1 / metabolism*
Thrombomodulin / metabolism*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Imidazoles; 0/Plasminogen Activator Inhibitor 1; 0/Thrombomodulin; 75438-57-2/moxonidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Short-term estrogen reduces myocardial infarct size in oophorectomized female rabbits in a dose-depe...
Next Document:  Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on...